drugset / Trial / NCT00408304

Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.

NCT00408304

Phase 2 Unknown 60 enrolled Bnai Zion Medical Center
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of the study is to check whether development of depression as a side effect of interferon alpha treatment in chronic carriers of hepatitis C can be prevented by omega-3 fatty acids.

Timeline

Start
2006-12
Primary completion
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lovaza Other / unclassified